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The Board of Licensure in Medicine has been extremely busy with complaints surrounding opioid prescribing. That 
should come as no surprise to most physicians given that every printing of the lay press is filled with news of the 
heroin epidemic and its horrific ramifications. Most authorities feel that narcotic overprescribing by physicians 
plays a role in fueling this epidemic. Recent legislation outlining restrictions/regulations on opioid prescribing by 
Maine physicians is designed to rein in narcotic prescribing. So the Board may well be seeing fewer complaints 
surrounding this issue. Time will tell.
There is another common theme in most complaints that the Board encounters, which is not so much in the news. 
Personal communication is the common denominator. If most of us stepped back and thought about it, we would 
agree. However, in our busy practicing lives of more and more patient encounters, electronic health record 
demands, endless workplace regulations and details, opportunities for reasonable, thoughtful, and empathetic 
communication often get short shrift. This situation can get physicians in trouble as leaders of the team in patient 
care.
Communication is first and foremost between the doctor and the patient, but it seldom stops there. More often than 
not it also includes guardians, family members, significant others and sometimes friends. Physicians are also 
required to interact appropriately with office and /or operating room staff to inspire and enable them to help and 
care for patients in the best possible ways. Good rapport amongst the medical team can make all the difference in 
critical situations.
Another aspect of problematic communication is due to the fact that the medical world has evolved into a spectrum 
of specialists so that people with specific ailments are segregated into specific areas with specialists, who all too 
often only see the patient through the lens of their own expertise. Communication among the various physicians 
involved in a patient's care is paramount for good, safe medical care, but often it is difficult to achieve. Although 
touted to do so, the electronic medical record has not solved this disintegration problem by a long shot.
Also, when patients are transferred to different care settings there needs to be personal communication with the 
receiving providers above and beyond filling out forms so that patients get their special needs met and receive the 
right care at the right time.
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Most doctors get caught up on the information we have to convey, but it is critical to pay attention to the manner of 
that conveyance as well. We can increase the likelihood of successful communication by adjusting the tone, the 
pace, the vocabulary, and the way we frame important issues to suit the needs of the person we are talking to.
So pause, take an extra few seconds to consider how to deliver the message. Lay the groundwork to coordinate the 
patient's care with effective, empathetic communication and hopefully you will avoid a complaint to the Board of 
Licensure in Medicine about failed or deficient communication.
Training in Risk Communication and Shared 
Decision Making
Paul Han, MD, MA, MPH 
For the past 5 years, the Center for Outcomes Research and Evaluation (CORE) at Maine Medical Center (MMC) 
has been developing and implementing innovative medical education programs to train clinicians in risk 
communication and shared decision making (SDM). 
1. Risk communication training program 
Since 2011, CORE has administered a successful training program in risk communication skills to 2nd-year medical 
students at Tufts University School of Medicine (TUSM). The original training program, known as “Risk Talk,” 
consisted of a 3-hour workshop integrating didactic and experiential training (role play) using standardized patients 
(SPs), as well as formative evaluation of students’ skills using Observed Structured Clinical Examination (OSCE).1
The program has since been integrated within a larger advanced communication skills training session for all 2nd-
year TUSM students, and now consists of a 70-minute experiential training workshop. The program has been 
adopted at Washington University School of Medicine (WUSM), and is currently being used as a model for a new 
risk communication training program at the Heidelberg University School of Medicine (Germany). Our group is 
exploring expanding the Risk Talk program to graduate and continuing medical education settings.
CORE has also developed tools to assess clinicians’ competence in risk communication. In 2011 we developed the 
only published observational measure of risk communication competence, the Risk Communication Content (RCC) 
Scale.1 Most recently in 2015, we developed a brief 4-item version of the measure, known as the Brief Risk 
Information SKill (BRISK) Scale; a manuscript reporting on the scale’s reliability and validity is currently under 
review.
2. Risk communication e-learning module
In 2014, CORE developed an e-learning module, “Risk Talk Online,” designed to provide didactic training on the 
principles of risk communication. The program integrated content from the workshop-based risk communication 
program, as well as professionally produced video recordings of an exemplary risk communication conversation 
between a physician and a patient, to facilitate observational learning. At TUSM, the e-learning module has been 
used in a “flipped classroom” approach, in which students view the module prior to the in-person advanced 
communication skills workshop, and classroom time is devoted to experiential training using role play. The 
program has been well-received by students and is currently also being used at WUSM, and its effectiveness in 
improving students’ risk communication knowledge is reported in a forthcoming publication.2
3. Shared decision making training program 
Through a grant from the Picker-Gold Foundation in 2015, CORE developed and pilot-tested a training program in 
SDM at the Graduate Medical Education level. The program was implemented among 4 residency programs at 
MMC: Family Medicine, Internal Medicine, Obstetrics/Gynecology, and Urology. The SDM training program 
consists of didactic training provided through educational in-services, as well as an e-learning module developed by 
collaborators at the Dartmouth Institute. The program also integrates experiential learning, provided either 
through direct clinical observation by faculty or through OSCEs conducted in a clinical simulation laboratory setting 
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with standardized patients. In 2016, this work will be extended to more residency programs at MMC (General 
Surgery, Pediatrics, Psychiatry), and a “train the trainer” faculty development toolkit will be developed and 
implemented to facilitate further dissemination of the program. 
_____________________________________________________________________________________ 
1. Han PK, Joekes K, Elwyn G, et al. Development and evaluation of a risk communication curriculum for medical 
students. Patient Educ Couns. 2014;94:43-9.
2. Han PK, Piccirillo J, Gutheil C, et al. Development and evaluation of an online risk communication teaching 
program for medical students. Med Sci Educ. 2016;(in press). 
Introduction to Staff
New Consumer Assistance Specialist, Savannah 
Okoronkwo
Savannah is a Maine native, born and raised in Windsor, Maine. 
She graduated from Erskine Academy and went on to work for 
Maine State Government for a number of years before coming to 
the Board of Licensure in Medicine (BOLIM). Prior to coming to the 
Board, Savannah worked at the Department of Health and Human Services shortly after completing high school. 
For two years, Savannah worked for Child Support Enforcement and then moved on to the Office of Substance 
Abuse and Mental Health Services where she worked from 2009-2016. Savannah is very passionate about this field 
and believes it is where she wants to eventually further her education. Savannah enjoys spending time with her 
family, and she and her husband, Emmanuel, who is a native of Nigeria, live in China with their twenty- month old 
daughter Natania. As the Consumer Assistance Specialist, Savannah is the primary point of contact for the public 
regarding BOLIM complaints and the Board’s investigative process. Savannah can be reached by email at 
Savannah.Okoronkwo@maine.gov and by phone at 287-3608. 
Investigative Secretary, Katie Feliciano
Katie has lived in Maine her whole life. She spent her early elementary school years on the coast in Phippsburg and 
graduated from Messalonskee High School in Oakland. Katie later completed additional education in 
Lewiston/Auburn and she is currently taking courses through the University of Maine at Augusta. Katie enjoys 
travelling to visit friends and family across the country, from New Mexico to New York. She resides in Lewiston 
with her boyfriend and their cat, Dinah, and enjoys creating art including painting, sketching and photography. As 
the Board’s investigative secretary, Katie is responsible for processing all complaints received by the Board, 
including sending out initial complaint notifications, obtaining medical records, and issuing notices of informal 
conferences and adjudicatory hearings. She is also the point of contact for licensees and their legal counsel. Katie 
can be reached by email at Katie.Feliciano@maine.gov and by phone at (207) 287-3625.
Complaint Coordinator, Julie Best
Julie was born in Maine, has a daughter and a son, and currently lives in Windsor with her family. Julie studied 
Biology and Business in Florida, and returned to Maine after her first child was born. She came to the Board of 
Medicine after working many years with the Maine Department of Labor assisting job seekers and employers. Julie 
was hired at the Board of Medicine 2 years ago and started as the Board’s Consumer Assistant. Currently, as the 
Board’s Complaint Coordinator, she is responsible for supervising the Complaint Unit and for monitoring licensee’s 
on probation. Julie finds her position at the Board of Medicine to be interesting and enjoys working with licensees, 
complainants and her Board of Medicine team. Julie is a nature lover and prefers to spend her time outside 
exploring and hiking with her family and her dog. Julie may be reached by email at Julie.A.Best@maine.gov and by 
phone at 207-287-6931 with questions about licensee monitoring or the Board’s complaint process. 
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The License Renewal Process
The Board receives many calls from licensees about the renewal process. This article will address three of the most 
common questions/concerns.
I did not receive notice that my renewal was due.
The Board sends all correspondence to the most recently designated contact address provided to it by an applicant 
or licensee. If the applicant’s or licensee’s designated contact address changes, and the applicant or licensee does 
not update the Board with the new one, all correspondence – including renewal notices – will go to the old 
designated contact address. Therefore, it is critically important for applicants and licensees to provide the Board 
with any changes to their designated contact address. Those who fail to do so will not receive a renewal notification 
and risk having their license expire, be administratively suspended, and lapse. Here’s how the renewal notification 
process works.
The Board sends out renewal notices to licensees sixty days in advance of their license expiration date. The renewal 
notices are sent to the most recent address provided to the Board by the licensee. On July 1st the Board sent 298 
notices to licensees whose licenses expire on August 31st. If history holds, between thirty and 50 of these notices 
will be returned to the Board because the licensee’s address has not been updated. 
Licensees who do not renew their license prior to the expiration date are sent a second notice informing them that 
their licensee has expired, but that they can renew their license within the next thirty days with a $100 late fee. The 
Board sends these notices to the most recent address provided by the licensee, even if the original sixty day notice 
letter was returned. The Board sent 67 of this type of notice on July 1st for licenses that expired June 30th.
Licensees who still don’t renew their license are sent a third notice that their license has been administratively 
suspended and they may no longer practice medicine in Maine, but they can still renew their licensee for thirty 
more days with a $100 late fee. These notices are sent certified and are again sent to the most recent address 
provided by the licensee. The Board sent 32 of these notices on July 1st at a cost of $6.46 per letter. Almost every 
one of these letters will be returned to the Board “unclaimed.”
Finally, if the license is still not renewed after sixty days the license lapses and a fourth notice is sent, again to the 
same address, indicating that the license has lapsed and must be reinstated if the licensee decides to practice in 
Maine again.
In all, the Board will spend about $2,000 this year on postage to licensees who have not updated their addresses.
When you apply for a license, and each time you renew that license, you are reminded to update your contact 
address. In addition, you are requested to specify to which address, home or business, the Board is to send 
correspondence. The Board will use the address that you designate. If your contact address changes, and you do not 
update the Board about that change, you will not receive your renewal notices. There are many different reasons 
licensees do not update their addresses between the renewal cycles. The most common reaction from licensees that 
their license has lapsed is amazement that they have to inform the Board of their contact address change. The most 
common problem with non-updated contact addresses involves employment. Many licensees designate that all 
Board correspondence be sent to their place of employment. This is problematic for many licensees who change 
employment, as many employers do not forward mail to former employees. 
The second most common problem is with new licensees. New licensees provide out of state addresses when they 
are applying for licensure, and then fail to update the address after they receive the license and start working in 
Maine. 
All applicants and licensees of the Board are required to notify the Board when they change their name, address, 
phone number or email from the one most recently provided. Those applicants and licensees who fail to provide 
this updated information risk not receiving important information such as renewal notices, complaint and 
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investigation notices or requests for additional information. You can update your name and contact information 
online at the Board’s website: https://www1.maine.gov/cgi-bin/online/licensing/begin.pl?Board_number=376
Do I need to take the jurisprudence exam?
When renewing online the system will automatically prompt you to take the exam if necessary. You will not be able 
to proceed with the renewal until a valid exam is on file in the system. The Board expects the licensee to take the 
exam every other renewal cycle, or approximately every four years. For example:
• Your renewal date is 7/31/16 and you last took the exam on 7/30/12. You are completing your renewal this 
year on 7/20/16. It has been less than four years, so do you need to take the exam? Answer – Yes. The exam is 
due every four years or every other renewal cycle. This is actually a common question and complaint. Just 
take the exam.
• I was licensed in September 2013, renewed in July 2014 and am renewing again in July 2016. I originally took 
the exam in September 2013, so do I need to take the exam again? Answer – No. You took the exam less than 
three years ago. Even though you are going through your second renewal cycle, so you do not need to take the 
exam. However, if you took the exam more than three years ago, you may be asked to complete the exam.
• I have an inactive license. Do I need to take the exam? Answer – Yes/No. If you are completing the renewal 
online and you are prompted to take the exam you must take the exam. If you are one of the few renewing on 
paper, you do not need to take the exam at renewal, but you will need to take it prior to returning to active 
practice.
• I don’t have an email address and renew on paper. How do I know when to take the exam? Answer – Once 
your renewal application is received your license will be placed in a pended status and a copy of the exam will 
be sent to you.
How does CME work?
You need to obtain 100 hours of CME every renewal cycle (new licensees may have their initial CME obligation 
prorated). At least 40 must be Category I and the remaining sixty can be either Category I or Category II. 
It is important to note that the CME requirement is based on your renewal cycle. It is not: 
• Based on the calendar year; nor is it
• Based on your specialty Board cycle.
We often hear from licensees who have not completed their CME requirement because they only follow the timing 
requirements of their specialty Board and insist that the Board should change its requirements to mirror those of 
private entities. That is not feasible.
Although the Board will work with licensees who have not completed their CME requirements, the Board will not 
renew the license until all requirements have been met. This delay should be avoided, as it can lead to awkward 
questions from employers and various difficulties with insurers. 
Opiate Dosages for Chronic Pain and/or Addiction
BOLIM’s April newsletter outlined the opioid epidemic in Maine, summarized the highlights of Maine’s new law 
regarding prescribing opioids, and announced BOLIM’s plan to introduce updated rules for prescribing controlled 
substances for pain. 
As dates for compliance with the new law approach, clinicians will face the challenge of tapering the opiate dosages 
for chronic pain patients who do not clearly meet the exclusion criteria for dose limits. This may cause patients to 
become anxious, upset and frustrated. Therefore, it is important for clinicians to recognize their patients’ fears of 
possible uncontrolled pain and withdrawal, and work with them collaboratively. The new law does not prohibit 
clinician’s from prescribing controlled drugs, and should not be a reason to simply stop prescribing, as this may 
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lead to complaints of abandonment or uncompassionate care due to inappropriately fast tapers leading to 
withdrawal or uncontrolled pain. Patients who are addicted to prescription opioids or even those who are opioid 
tolerant and in pain, may feel compelled to seek out illegal drugs, which may result in overdose and death. It is also 
important for clinicians to distinguish between patients who are addicted to opioids, with or without chronic pain, 
and those who may be physically dependent on opioids as the treatment needs can be quite different. 
Many clinicians find it gratifying to treat patients who are suffering from addiction and help empower them to make 
positive changes in their lives. The Drug Addiction Treatment Act of 2000 (DATA 2000), greatly expanded access 
to treatment for addiction by allowing qualified physicians (MD, DO) to offer office based medication assisted 
treatment (MAT). Buprenorphine offers safe and effective treatment for both long term maintenance as well as 
medically supervised withdrawal from opioids. MAT with buprenorphine is most effective in combination with 
counseling services, which can include behavioral therapy and self- help programs. (1) Buprenorphine has 
properties that make it ideal for helping patients who are addicted to opioids, but it is important to understand the 
pharmacology in order to avoid unintended consequences.
Buprenorphine is a semi-synthetic opioid which acts as a partial agonist at the mu opioid receptor and an 
antagonist at the kappa receptor. It has very high affinity and low intrinsic activity at the mu receptor and will 
readily displace morphine, methadone, and other full opioid agonists from the receptor. In doing so, it can deter 
addicts from using other opioids by blocking their activity. However, because of its low intrinsic activity at the mu 
receptor, its effects are not linear with increasing doses; it exhibits a ceiling on its agonist effects, so is not 
considered a powerful anesthetic. One consequence of the ceiling effect is that an overdose of buprenorphine is less 
likely to cause fatal respiratory depression than might a full mu opioid agonist. But its agonist effects are often 
enough to help addicts “feel normal.”
For patients who are physically dependent and taking regular doses of opioids, buprenorphine’s antagonist 
properties can cause acute withdrawal. In this situation, buprenorphine can displace enough of the full agonist 
opioid from the mu receptors, yet not provide the equivalent degree of receptor activation, leading to the onset of 
withdrawal, and maybe pain if that co-morbidity exists. Also because of the high affinity of buprenorphine for the 
opioid receptor, adequate pain control might be hard to achieve in a patient on buprenorphine maintenance who 
needs emergent surgery or who has acute trauma. 
Buprenorphine can produce euphoria, especially if injected. It can cause physical dependence although it appears to 
do so to a lesser degree than do full opioids. It must be tapered off slowly and full termination can be difficult. Some 
patients may require long term administration of buprenorphine. Side effects are similar to full opioids. Overdose is 
possible at high dose if taken with other respiratory depressants like alcohol or benzodiazepines.
Buprenorphine can be abused, particularly by people who do not have an opioid dependency. Naloxone is added to 
buprenorphine (Suboxone) to decrease the likelihood of diversion and misuse of the combination drug product. 
Buprenorphine has poor GI bioavailability but good sublingual bioavailability. Naloxone has poor GI and sublingual 
bioavailability. Thus, if the combination tablet is taken as directed sublingually, the patient gets a primarily weak 
opioid effect, but if an individual dissolves and injects it IV, the antagonistic effects of the naloxone predominates. 
As with any prescription opioid, clinicians should monitor patients closely for signs of diversion or misuse, 
especially if buprenorphine alone is used.
Subutex (buprenorphine alone), Suboxone (buprenorphine plus naloxone, 4:1), and Probuphine (the first 
buprenorphine implant for the maintenance treatment of opioid dependence) are the only Schedule III drugs 
approved by the FDA for use in office-based treatment of opioid addiction by clinicians. In order to prescribe these 
medications for the treatment of addiction, clinicians must apply for a DATA 2000 or X waiver from the DEA. To 
qualify, clinicians must hold a state license and a schedule III DEA registration. They must also complete at least 8 
hours of approved training in the treatment of opioid addiction, or have other qualifications, like certification in 
addiction medicine, and must attest that they can provide or refer patients to necessary, concurrent psychosocial 
services. The Substance Abuse and Mental Health Services Administration (SAMHSA) web site 
http://www.samhsa.gov/medication-assisted-treatment, has all necessary information on CME courses, waiver 
forms and physician support services . In addition to these requirements, DATA limits the number of patients that a 
physician is permitted to treat at any one time to 30 in the first year after obtaining a waiver. If they wish to treat 
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more than 30 patients after the first year, they must file an application with the DEA to extend his or her waivered 
capacity to the new limit of 275 patients which takes effect August 8, 2016. The previous limit was 100 patients.
Waivered physicians are not permitted to delegate the prescribing of buprenorphine for the treatment of addiction 
to nurse practitioners or physician assistants, but on July 22, 2016, the Comprehensive Addiction and Recovery Act 
of 2016 (S.524 CARA ) was signed into law and will allow PAs and NPs to obtain their own waivers to treat 
addiction with buprenorphine. (4) Rules regarding this are pending from DHHS, so stay tuned for more 
information.
There is an exemption, known as the three day rule, that allows non-waivered physicians to administer (but not 
prescribe) narcotic drugs, such as buprenorphine, to a patient for the purpose of relieving acute withdrawal 
symptoms while arranging for the patient’s referral for addiction treatment, under the following conditions: 1) not 
more than one day’s medication may be administered or given to a patient at one time; 2) this treatment may not be 
carried out for more than 72 hours; and 3) this 72-hour period cannot be renewed or extended. Details can be found 
at http://www.deadiversion.usdoj.gov/drugreg/faq.htm.
A patient with an opioid dependency who is admitted to a hospital for a primary medical problem other than opioid 
dependency, such as myocardial infarction, may be administered opioid agonist medications such as methadone 
and buprenorphine to prevent opioid withdrawal that would complicate the primary medical problem. It is good 
practice, however, for the admitting physician to consult with the patient's substance misuse treatment provider, 
when possible, to obtain treatment history.
DEA record keeping requirements for office-based treatment of opioid dependency go beyond the Schedule III 
record keeping requirements. According to DEA, clinicians must keep records (including an inventory that accounts 
for amounts received and amounts dispensed) for all controlled substances and shall not store and dispense 
controlled substances that are the result of filled patient prescriptions. (5)
The FDA has approved Buprenex (injectable formulation of buprenorphine) and Butrans (transderm patch) to treat 
pain, but not opioid dependence. Suboxone, Subutex and Probuphine are FDA-approved to treat opioid dependence 
but not to treat pain. Thus, any prescription use of Suboxone and Subutex to treat pain is considered “off-label,” an 
unapproved but not illegal use of these medications. (6) In some areas of Maine, clinicians use buprenorphine for 
short term treatment of moderate acute pain. In these cases, knowledge of the pharmacokinetics of buprenorphine 
is important, the documented rational for use must be very clear, and it is recommended to label the prescription 
for acute pain. 
Patient’s being treated for opioid addiction with Suboxone who develop conditions causing acute pain may find it 
difficult to get the care they need because clinician’s may feel wary of prescribing opioids in these patients. Yet they 
deserve a full evaluation and treatment of their pain. Prompt consultation with a pain or addiction specialist may be 
prudent.
The SAMHSA-funded Physician Clinical Support System (PCSS-B) is designed to assist practicing physicians 
incorporate buprenorphine treatment of prescription opioid and heroin dependent patients into their practices. 
Physicians may use this resource for assistance in obtaining a mentor for beginning an office-based practice. The 
PCSS-B service is available at no cost to interested physicians and staff at http://pcssmat.org. Physicians can also 
join the SAMHSA Buprenorphine Clinical Discussion WebBoard to ask and discuss questions on the clinical use of 
buprenorphine.
Concern about the lack of access to treatment for opioid addiction and the need for education on the compassionate 
tapering of patients on high dose opioids has led to quick action by Maine Quality Counts 
(https://www.mainequalitycounts.org) and the Maine Medical Association (https://www.mainemed.com) to try to 
get more clinician’s trained in these areas, and anyone interested is encouraged to check their websites. Quality 










(4) S.524 Comprehensive Addiction and Recovery Act of 2016
https://www.govtrack.us/congress/bills/114/s524
https://www.govtrack.us/congress/bills/114/s524/text
(5) Clinical Guidelines For The Use Of Buprenorphine In The Treatment Of Opioid Addiction
http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf
(6) http://pcssmat.org/wp-content/uploads/2014/02/PCSS-MATGuidanceOff-label-bup-for-pain.Gordon.pdf
From the Executive Director’s Desk
Maine Medical Boards Adopt Joint Rule for Physician Assistants
Background
The Maine Board of Licensure in Medicine and the Board of Osteopathic Licensure have adopted “Chapter 2 Joint 
Rule Regarding Physician Assistants.” The joint rule implements Public Law 2015, Chapter 242, as amended, which 
was designed to eliminate the dual licensure of physician assistants in Maine. Prior to that law change, physician 
assistants were required to be licensed and registered with each board if they provided medical services under the 
delegation of an allopathic physician and an osteopathic physician. The new law eliminates this requirement and 
allows a physician assistant to practice under an allopathic or osteopathic physician when licensed and registered 
with either board. Prior to the enactment of the Chapter 2 Joint Rule, each board had its own rules regarding 
physician assistants, which were not identical. The Chapter 2 Joint Rule eliminates this discontinuity, and creates 
uniform: 
• Definitions
• Qualifications for licensure
• Requirements for registration
• Applications for licensure and registration
• Fees
• Scope of practice
• Standards for physician supervision of physician assistants





Here are some of the important aspects of the Chapter 2 Joint Rule: 
• Physician assistants will be licensed with only one board
• Physician assistants who are currently licensed by both boards will need to select the board with which they 
want to continue to be licensed
• Physician assistants require both a license and a registration in order to render medical services
• Physician assistants may prescribe Schedule II-V drugs so long as the prescribing authority is specifically 
delegated in the written plan of supervision
• Physicians are responsible for the prescribing practices of the physician assistants under their supervision
• Physician assistants must notify the boards in writing within 10 calendar days of any of the following:
◦ Change of primary supervising physician
◦ Termination of the plan of supervision
◦ Change of contact information 
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◦ Death/Departure of supervising physician
◦ Failure to pass NCCPA exam
◦ Criminal arrest/summons/indictment/conviction 
◦ Change in employment or hospital privileges
◦ Disciplinary action
◦ Material change in any answers to questions on applications
The Chapter 2 Joint Rule is available on the boards’ websites:
http://www.maine.gov/md/
http://www.maine.gov/osteo/
As of 8/1/16 the Federal Drug Enforcement Administration (DEA) has removed the schedule restrictions from all 
Federal DEA registrations for PA’s in the State of Maine. 
PAs desiring to add drug schedules to their Federal DEA registrations should do so by using the DEA web site: 
www.deadiversion.usdoj.gov PLEASE DO NOT TO CALL THE BOSTON DEA OFFICE. The DEA will update 
registrations as quickly as possible, but will need a few days to process the request.
Adverse Actions
Jack L. Flippo, M.D. License #MD21015 (Date of action June 16, 2016) On June 16, 2016, the Board 
entered into a Consent Agreement for licensure with Dr. Flippo based upon disciplinary action taken by theNorth 
Carolina Medical Board. The Consent Agreement requires Dr. Flippo to comply with all terms and conditions of a 
December 2, 2015 North Carolina Medical Board Consent Order, a monitoring contract with the North Carolina 
Physicians Health Program, and a monitoring contract with the Maine Medical Professionals Health Program.
James Grossman, PA-C License #PA44 (Date of action June 16, 2016) On June 16, 2016, the Board 
entered into a Consent Agreement with Mr. Grossman finding that Mr. Grossman had engaged in incompetence 
and unprofessional conduct for prescribing scheduled drugs on several occasions to a person who was not his 
patient. The Board imposed a reprimand, a civil penalty of one thousand dollars ($1,000.00), and a license 
probation for at least ten (10) months which includes requirements that Mr. Grossman attend an in-person 
continuing medical education course of not less than twenty (20) hours on the subject of professional boundaries, 
attend an in-person continuing medical education course of not less than six (6) hours on the subject of prescribing 
opioids and the use of universal precautions, and chart reviews.
Robert S. LaMorgese, M.D. License #MD19083 (Date of action June 16, 2016) On June 16, 2016, the 
Board issued a Decision and Order following an adjudicatory hearing held on May 10, 2016. The Board found that 
because Dr. La Morgese had not actively engaged in the practice of medicine since early 2014, he engaged in 
conduct that evidences a lack of ability or fitness to discharge the duty owed by the licensee to patients and imposed 
a period of probation for six (6) months during which Dr. LaMorgese agrees to retain a Board approved practice 
monitor and to obtain a neurological evaluation by a Board approved neurologist. In addition, if Dr. LaMorgese 
reactivates his DEA registration, he must complete an in-person continuing medical education course of at least 
eight (8) hours on the topic of prescribing opioids.
James F. McGuckin, M.D. License #MD19821 (Date of action May 10, 2016) On May 10, 2016, the Board 
entered into a Consent Agreement with Dr. McGuckin imposing discipline resulting from disciplinary action taken 
by the State of Washington Medical Quality Assurance Commission in October 2015. The Consent Agreement 
requires that Dr. McGuckin comply with all requirements imposed by the State of Washington Medical Quality 
Assurance Commission Order, and specifies that he shall not perform angioplasty and stenting procedures of the 
venous system for CCSVI or multiple sclerosis patients in the State of Maine. 
Edison P. McDaniels, II, M.D. License #MD19821 (Date of action May, 10, 2016) On May 10, 2016, the 
Board entered into a Consent Agreement with Dr. McDaniels imposing a warning and a civil penalty of one 
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thousand dollars ($1,000.00) for misrepresentation in obtaining a license, i. e., for his failure to disclose all 
malpractice settlements on his license applications. 
Sharon Marble, M.D. License #MD16567 (Date of action April 12, 2016) On April 12, 2016, the Board 
entered into a cConsent aAgreement with Dr. Marble based upon the Board finding that Dr. Marble engaged in 
incompetence and unprofessional conduct by having a romantic relationship with a patient/former patient for 
whom she had provided mental health treatment. The Board imposed a censure, a license probation for five years, a 
fifteen hundred dollar ($1,500.00) civil penalty, and requirements that Dr. Marble enroll in a Board approved 
medical ethics/ professional boundaries course within nine months, terminate her relationship with the former 
client, and obtain a substance abuse evaluation. In addition, Dr. Marble’s license to practice medicine is limited to 
the practice of administrative medicine for at least two years.
Donald B. Shea, M.D. License #MD18015 (Date of action April 12, 2016) On April 12, 2016, the Board 
entered into an interim consent agreement with Dr. Shea providing for the immediate suspension of his license to 
practice medicine after acknowledging that existing evidence could provide a basis for the Board to conclude that 
the continued licensure of Dr. Shea as a physician would place the health and physical safety of the public in 
immediate jeopardy. The suspension of Dr. Shea’s license shall continue until a pending complaint alleging that Dr. 
Shea misused alcohol, drugs or other substances that has resulted or may result in the licensee performing services 
in a manner that endangers the health or safety of patients, engaged in the practice of fraud, deceit or 
misrepresentation in connection with service rendered within the scope of the license issued, and engaged 
unprofessional conduct is resolved.
William Silber, M.D. License #MD12320 (Date of action April 8, 2016) On April 8, 2016 Dr. William 
Silber requested to withdraw his application for renewal of licensure while under investigation. On April 12, 2016, 
the Board approved his request to withdraw. Should he decide to apply again for a Maine license in the future, he 
will be required to meet all licensure requirements in effect at the time of application and the Board may consider 
whether any grounds exist to deny the application, including grounds for denial that may arise out of the conduct 
that gave rise to the investigation.
Charles D. Clemetson, M.D. License #MD13808 (Date of action March 9, 2016) On March 9, 2016, the 
Board issued a Decision and Order following an adjudicatory hearing that was held on February 9, 2016. The Board 
found that Dr. Clemetson engaged in misrepresentation in connection with the practice of medicine by requesting 
Board approval of an individual as his Board ordered practice monitor while knowing that he was unlikely to 
continue working with that individual, and by not subsequently informing the Board that he had ceased using that 
individual as a monitor after just one meeting. The Board also found that Dr. Clemetson had engaged in 
unprofessional conduct by violating a standard of professional behavior in the practice of medicine by practicing 
without a practice monitor for a period of 31 months after being ordered not to do so, by not communicating the 
status of his practice monitor, and by falsely representing that he was using an electronic records system to the 
Board. Finally the Board found that Dr. Clemetson had failed to comply with the conditions of probation imposed 
pursuant to the July 11, 2013 Decision and Order. The Board imposed a censure, and a license probation for five 
years. Dr. Clemetson must close his private practice within 90 days, and is limited to practicing in a setting with 
other physicians and with a Board approved practice monitor who will report to the Board.
Ajitpal S. Dhaliwal, M.D. License #MD20397 (Date of action March 8, 2016) On March 8, 2016, the 
Board entered into a Consent Agreement with Dr. Dhaliwal based upon the Board concluding that Dr. Dhaliwal 
engaged in misuse of alcohol, drugs or other substances in a manner that may result in performing services in a 
manner that endangers the health or safety of patients, and unprofessional conduct The Consent Agreement 
requires that Dr. Dhaliwal be subject to a two year license probation with conditions that include compliance with 
and participation in an agreement with the New York Committee for Physician Health that includes toxicology 
monitoring and abstinence from any non-prescribed substances.
Brandon W. Chan, M.D. License #MD20448 (Date of action March 8, 2016) On March 8, 2016, the 
Board entered into a Consent Agreement with Dr. Chan based upon the Board concluding that Dr. Chan engaged in 
unprofessional conduct and misrepresentation in obtaining a license by failing to report an existing complaint 
against him in another state on his application and failing to timely respond to a complaint notification sent by the 
Board. The Consent Agreement imposes a warning, a civil penalty in the amount of fiftenn hundred dollars ($1,500) 
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and requires Dr. Chan to notify the Board within ten days of any change to his contact information or the 
commencement of practice in Maine.
Ron Mark, M.D. License #MD18634 (Date of action March 8, 2016) On March 8, 2016, the Board entered 
into a Consent Agreement with Dr. Mark based upon the Board concluding that Dr. Mark engaged in unprofessional 
conduct and misrepresentation by failing to disclose pending medical malpractice claims, medical malpractice 
settlements, and disciplinary complaints and action on applications for license renewal. The Consent Agreement 
imposes a reprimand, and a civil penalty in the amount of three thousand dollars ($3,000). 
Online Renewal Notification Option
To E or not to E?
The Board is considering changing the way it notifies its licensees it is time to renew their licenses. As shown in the 
2015 Annual statistics, 96% of licensees are renewing their licenses online. Currently the Board sends those 
notifications through the mail. Each year hundreds of these notices are returned because licensees have not updated 
their addresses, as required by 32 MRS §3300-A. This amounts to a waste of both staff resources and money.
Based on this information, the Board is considering notifying its licensees of renewal by e-mail. When there is no 
record of an e-mail address the notification would be sent by US mail.
The Board is seeking comments from its licensees prior to making a decision. If you have comments, 
please e-mail them to the Board’s Executive Director, Dennis Smith, at Dennis.E.Smith@maine.gov
We look forward to hearing your opinion.
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